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Abstract
Background: Inequalities in survival from colorectal cancer (CRC) across socioeconomic groups and by area of
residence have been described in various health care settings. Few population-wide datasets which include
clinical and treatment information are available in Australia to investigate disparities. This study examines
socio-demographic differences in survival for CRC patients in South Australia (SA), using a population-wide
database derived via linkage of administrative and surveillance datasets.
Methods: The study population comprised all cases of CRC diagnosed in 2003-2008 among SA residents
aged 50-79 yrs in the SA Central Cancer Registry. Measures of socioeconomic status (area level), geographical
remoteness, clinical characteristics, comorbid conditions, treatments and outcomes were derived through record
linkage of central cancer registry, hospital-based clinical registries, hospital separations, and radiotherapy services data
sources. Socio-demographic disparities in CRC survival were examined using competing risk regression analysis.
Results: Four thousand six hundred and forty one eligible cases were followed for an average of 4.7 yrs, during which
time 1525 died from CRC and 416 died from other causes. Results of competing risk regression indicated higher risk of
CRC death with higher grade (HR high v low =2.25, 95 % CI 1.32-3.84), later stage (HR C v A = 7.74, 95 % CI 5.75-10.4),
severe comorbidity (HR severe v none =1.21, 95 % CI 1.02-1.44) and receiving radiotherapy (HR = 1.41, 95 % CI 1.18-1.68).
Patients from the most socioeconomically advantaged areas had significantly better outcomes than those from the least
advantaged areas (HR =0.75, 95 % 0.62-0.91). Patients residing in remote locations had significantly worse outcomes than
metropolitan residents, though this was only evident for stages A-C (HR = 1.35, 95 % CI 1.01-1.80). These disparities were
not explained by differences in stage at diagnosis between socioeconomic groups or area of residence. Nor were they
explained by differences in patient factors, other tumour characteristics, comorbidity, or treatment modalities.
Conclusions: Socio-economic and regional disparities in survival following CRC are evident in SA, despite having
a universal health care system. Of particular concern is the poorer survival for patients from remote areas with
potentially curable CRC. Reasons for these disparities require further exploration to identify factors that can be
addressed to improve outcomes.
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Background
Rates of colorectal cancer (CRC) in Australia are
among the highest in the world [1]. CRC is the second
most commonly reported cancer in Australia, after
prostate cancer and second most common cause of
cancer death, after lung cancer, with approximately
16,000 new cases and 4000 deaths in 2012 [2]. The cost
of managing and treating CRC exceeds that for any
other cancer, surpassing A$427 million for 2008/09 [3].
While survival from CRC is relatively favourable, out-
comes are highly dependent on stage at diagnosis. Cur-
rently in Australia, five year relative survival is 86 % for
localised CRC compared with 66 % for regional disease
and only 12 % for distant spread [4]. However, only one
third of CRCs are ‘localised’ at diagnosis [5]. Earlier de-
tection of CRC should therefore lead to substantial im-
provements in survival [6].
Reducing inequalities is an increasingly important
focus of cancer control efforts, alongside improving
survival overall. Socioeconomic and regional inequal-
ities in survival from CRC have been observed inter-
nationally [7–16], and in Australia [17–19], despite
many countries having universal healthcare. Reasons
for sociodemographic differences in outcomes are not
clear. Lower socioeconomic status (SES) is generally as-
sociated with later stage at diagnosis, and in some set-
tings, poorer standards of care, less favourable health
behaviours, and, or greater co-morbidity [20, 21]. Geo-
graphic variation may be due to lack of access to cancer
screening and diagnostic services leading to later stage
at diagnosis. Increased distance to cancer treatment
services may deter or restrict patients from accessing or
completing treatment, leading to disparities in treat-
ment with consequent impacts on survival among rural
patients [22–24]. Additionally limited follow-up facil-
ities in remote locations may impact survival.
National data for Australia indicate disparities in CRC
survival according to remoteness of residence and socio-
economic status at the area level [3]. Five-year relative
survival for remote residents was 62.8 % compared with
67.2 % for those living in major cities, and 64.5 % for
those residing in the lowest SES quintile compared with
69.4 % in the highest SES quintile. Whether these dis-
parities reflect differences in stage at diagnosis is unclear,
due to the lack staging information in Australian cancer
registries. Nor have any national or state-wide studies
been undertaken covering both the public and private
sector that include stage, comorbidity and treatment
data to disentangle the impact of these factors on socio-
economic disparities.
This study aimed to identify factors associated with
disparities in CRC survival using population-wide data
from South Australia. Specifically we examined whether
CRC survival differs according to area level measures of
socioeconomic disadvantage and remoteness of resi-
dence. We also examined factors associated with stage
at diagnosis, which may in part explain any survival dif-
ferences we observe. We hypothesis that we should not
see any disparities in survival according to area-level
measures of disadvantage, after adjustment for stage,
treatment and comorbidities, since healthcare is freely
available to all Australian residents. On the other hand
we would expect survival to vary according to place of
residence, with poorer outcomes for more isolated resi-
dents due to limited access to healthcare services.
In Australia, healthcare services are generally delivered
at the State level, along with administrative and surveil-
lance data systems accompanying service delivery. Thus,
population-based health services research is most feas-
ible at the state level. While the population of South
Australia is relatively small (1.5 million, approximately
8 % of Australia’s total population), the geographic and
socioeconomic variation across the state makes it an
ideal population in which to explore disparities in CRC
survival. Given the commonality in healthcare models
across states, and the similarity with the nation-wide
population profile, findings from South Australia will
give insight into the nature of disparities at the national
level. Further, they may confirm international findings
suggesting socioeconomic and regional disparities in
CRC survival despite universal healthcare.
Methods
Data sources and linkage
The study population comprised SA residents diag-
nosed with CRC (ICD10 C18-20) from January 2003 to
December 2008, aged 50 and 79 years, identified from
the South Australia Cancer Registry (SACR). This age
range and diagnostic period corresponds to cases that
were staged for a previous study on bowel cancer
screening. Cases of squamous cell carcinoma, melan-
oma, carcinoid and baseloid tumours, perianal Paget’s
disease, gastrointestinal stromal tumours and cancers
of unknown primary origin were excluded, since they
are generally staged and managed quite differently. Syn-
chronous colon and rectal cancer cases (n = 47) were
classified together with rectal cancers.
A mixture of probabilistic and deterministic linkage
methods were used to develop a comprehensive
population-wide dataset incorporating demographic,
clinical and outcome data for all CRC cases. SACR
records pertaining to eligible cases constituted the
core dataset. Linkage between the SACR and public
hospital separation data was undertaken by SANT
DataLink using probabilistic matching based on name,
address and date of birth, to retrieve records pertain-
ing to all admissions for each individual, which in-
cluded an admission code for CRC. Linkage between
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the SACR and private hospital separation data, radiother-
apy services and hospital-based cancer registries was
undertaken by the Department of Health through direct
matching of hospital codes, patient record numbers,
cancer registry accession number and personal identifiers,
again to identify all relevant records pertaining to CRC
diagnosis or treatment from these data sources. SANT
DataLink linkage processes followed the best practice
principle of ‘data separation’ to ensure privacy and ano-
nymity [25]. Figure 1 shows the data sources and linkage
processes used in the construction of this dataset.
Measures
All eligible cases had previously been manually staged
by SACR staff for a previous study [5], according to
Australian Clinico-Pathological Staging (ACPS) criteria
[26], based on data from pathology reports, supplemented
by electronic patient records and hospital-based cancer
registry (HBCR) data. Grade of the primary tumour at
diagnosis was extracted from SACR records and was
coded as low, intermediate or high grade corresponding to
well-differentiated, moderately-differentiated and poorly-
differentiated tumours based on pathological findings.
Stage and grade were unknown in 278 (6.0 %) and 362
cases (7.8 %), respectively.
Area of residence was classified into 5 categories:-
inner urban (very accessible), outer urban (moderately
accessible), rural (accessible), remote and very remote,
according to the Accessibility/Remoteness Index of
Australia, 2006 [27], based on residential postcode at
diagnosis as recorded by the SACR. This measure de-
scribes place of residence according to road distance
from population service centres. Remote and very re-
mote categories were combined for analyses due to small
Fig. 1 Data sources and linkages used to compile study dataset
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numbers. Similarly, an area level measure of SES was
assigned using the Index of Relative Socioeconomic
Advantage and Disadvantage (IRSAD) 2006 [28],
based on residential postcode. This index measures
area-level rather than individual-level characteristics
and represents the average socioeconomic status of
specified neighbourhoods (in this case postal areas). It
incorporates factors such as average household income,
education levels and unemployment rates. SES was
categorised into quintiles corresponding to SA's popula-
tion distribution. No individual level measures of SES
were available. Private health insurance status was
assigned if any individuals’ hospital admissions flagged the
patient as being privately insured. Patient co-morbidity
was assessed using the Charlson co-morbidity index (CCI)
[29] for the patient’s first admission for surgical treatment
or their first admission for CRC if there was no surgical
admission. Diagnosis codes for CRC and metastatic dis-
ease were excluded when calculating the CCI. CCI scores
were further categorised into no co-morbidity (CCI = 0), a
single co-morbidity (CCI =1) or multiple co-morbidities
(CCI > =2).
Treatments were assessed from multiple sources and
coded dichotomously (yes/no) based on any indication
in any data source (i.e. any procedure codes for relevant
treatment in hospital admissions, HBCR or radiotherapy
records). ‘Primary treatment’ was defined as treatment
commencing within 12 months of diagnosis, based on
the date of the first hospital admission or the treatment
start date in the HBCR or radiotherapy datasets if there
was no hospital admission record for that treatment.
Information about vital status was derived from the
SACR, which routinely links with state and national
death notifications to track dates and causes of death oc-
curring in any Australian jurisdiction.
Analysis
Ordinal logistic regression was undertaken to identify
factors independently associated with stage at diagnosis.
ACPS stage, categorised as four separate stages (A-D),
was the dependent variable. Unknown stage was
excluded. Adjusted odds ratios were obtained from a
multivariate model adjusting for all covariates simultan-
eously (age group, sex, cancer site, SES (quintiles), place
of residence, co-morbidity, primary surgery, radiother-
apy, and chemotherapy, and calendar year of diagnosis
(continuous). Cancer-specific survival was examined
crudely, in the first instance, using Kaplan-Meier prod-
uct limit estimates without taking competing risk into
account, with differences assessed using log rank tests.
We then assessed factors independently associated with
risk of CRC death, using competing risk regression ana-
lysis according to the method of Fine and Gray [30],
where death from other causes was the competing risk.
Cases were censored on December 31, 2012 or at their
date of death (whichever occurred earlier). Follow-up
time was calculated as the time from the date of
diagnosis to the censoring date or date of death if
death occurred before this date. Multivariable models
included cancer site, stage, grade, age, sex, year of
diagnosis, comorbidity categories, SES, place of resi-
dence, and primary treatments received. Cases with
missing stage were excluded from analyses, whereas
cases with missing grade were included as a separate
‘unknown’ category. We repeated the competing risk
analysis with imputed data for missing stage and
grade, derived using multiply imputed chained equa-
tions [31], with 20 imputed data sets. Only complete
case analyses are reported since results did not differ
substantially for multiply imputed data. All analyses
were undertaken using Stata v12.0 software [32].
This study received ethical approval from Human Re-
search Ethics Committees of SA Health, the Royal Adel-
aide Hospital, Flinders University/Medical Centre and the
SA Aboriginal Health Council, along with data access ap-
proval from SA Health for government managed datasets.
Results
Dataset profile
Of the 4949 CRC cases identified from the SACR, 113
were excluded due to ineligible histology, and 195 due to
lack of hospital admission records, leaving a total of
4641 for analysis. The average period of follow-up was
4.7 yrs, corresponding to 6.3 yrs among survivors and
2.3 yrs among those who died of CRC or other causes.
Demographic and clinical characters of the study cohort
are presented in Table 1.
Stage at diagnosis
In unadjusted analyses, distribution of stage at diag-
nosis did not differ by remoteness of residence or
SES, but did differ by cancer site, age group, extent
of comorbidity and health insurance status (Table 2).
Multivariate analysis using ordinal logistic regression
indicates that later stage was less likely among rectal
cancer cases (0R = 0.81, 95 % CI 0.72-0.91), older pa-
tients (0R = 0.77, 95 % CI 0.67-0.89 for 70-79 yrs v
50-59 yrs) and privately insured patients (OR = 0.84,
95 % CI 0.75-0.95) and more likely for those with co-
morbidities (OR = 1.50, 95 % CI 1.26-1.79 for CCI > = 2 v
0). Stage at diagnosis was not associated with socioeco-
nomic status (area-level), place of residence, or sex in
multivariate analyses.
Survival outcomes
CRC specific survival was 88 %, 75 % and 69 % at 1, 3
and 5 years respectively (Table 3). In crude analysis, sur-
vival was strongly associated with stage of disease, grade
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of tumour, age at diagnosis and severity of co-morbid
conditions. Survival was also associated with receipt of
specific treatments (with better survival among those
having surgery compared with no surgery and worse sur-
vival for those who had radiotherapy or chemotherapy
compared with those not receiving these treatments.
There were no significant differences by place of resi-
dence but survival did differ across SES quintiles and
according to whether patients were privately insured.
Multivariate competing risk regression (Table 4) re-
vealed similar results, though there were some slight
differences to crude survival analyses. Risk of CRC
death was higher among patients with later stage dis-
ease (e.g. HR = 7.74, 95 % CI 5.75-10.4 for stage C vs
stage A), higher grade (HR = 2.25, 95 % CI 1.32-3.84
for high verses low grade), and severe or multiple co-
morbidities compared with no comorbidity (HR = 1.22,
95 % CI 1.02-1.44) and lower among rectal compared
with colon cancer patients (HR = 0.85, 95 % CI 0.72-
0.98). However there were no significant differences
by age group or by health insurance status after
adjusting for other covariates and accounting for death
from other causes. Risk of CRC death was significantly
lower among those who underwent surgery (HR = 0.51
95 % CI 0.42-0.62) and higher among those who received
radiotherapy (HR = 1.41, 95 % CI 1.18-1.68), but unlike
crude analyses, CRC death was lower among those who
received chemotherapy (HR = 0.87 95 % CI 0.76-1.00). No
differences were found according to place of residence,
however risk was significantly lower among the highest
compared with lowest SES group (HR = 0.75, 95 % CI
0.62-0.91). Risk of CRC death declined significantly over
the study period (HR = 0.95, 95 % CI 0.92-0.98).
Results of stratified analyses, restricted to cases with
potentially curable (stages A-C), or metastatic disease
(stage D), are shown in Tables 5 and 6. For poten-
tially curable disease, risk of CRC death was higher
among residents from remote regions compared with
metropolitan residents (HR = 1.35, 95 % CI 1.01-1.80).
Regional differences were not evident among patients
with stage D CRC at diagnosis. Risk CRC death was
lower among those in the highest compared with low-
est socioeconomic quintile, both among those with
potentially curable CRC (HR = 0.80, 95 % CI 0.63-
1.01, non-significant) and for those with metastatic
cancer (HR = 0.65, 95 % CI 0.47-0.89). Also private
insurance was associated with improved outcomes
(HR = 0.80, 95 % CI 0.67-0.96) among patients with
metastatic disease at diagnosis but no difference was
observed for those with stage A-C CRC. There was
no evidence of improvement in survival for metastatic
CRC patients over the study period, whereas there
was a trend toward improved survival (reduced risk
of death) over time for patients with stage A-C CRC
(HR = 0.93, 95 % CI 0.90-0.97). Figure 2 shows the
cumulative mortality plots for CRC mortality, adjusted
for covariates and competing risk of death from other
causes by neighbourhood SES, for all cases, and place
of residence for stage A-C CRC.
Table 1 Characteristics of the study population (CRC diagnosed
among SA residents 50-79 yrs, 2003-2008)
Factor Total no. (%)
Total Number (% of total) 4641 (100)
Sex Female 1973 (42.5)
Male 2668 (57.5)
Age 50-59 yrs 959 (20.7)
60-69 yrs 1601 (34.5)
70-79 yrs 2085 (44.8)
Place of Inner urban 3304 (71.2)
residence Outer urban 459 (10.0)
Rural 621 (13.4)
Remote 257 (5.5)
Socioeconomic Lowest quintile 1120 (24.1)
status Mid-low 939 (20.2)
Mid 849 (18.3)
Mid-high 897 (19.3)
Highest quintile 836 (18.0)
Private Insurance No 2082 (44.9)
Yes 2559 (55.1)
Year 2003 789 (17.0)
2004 771 (16.6)
2005 722 (15.6)
2006 744 (16.0)
2007 828 (17.8)
2008 787 (17.0)
Stage# A 933 (20.4)
B 1438 (30.1)
C 1345 (28.0)
D 649 (14.0)
unknown 278 (6.0)
Grade Low 123 (2.7)
Intermediate 3293 (71.0)
High 863 (18.6)
unknown 362 (7.8)
Comorbidity* None 3236 (69.7)
Single comorbidity 819 (17.7)
Severe or multiple 586 (12.6)
Site Colon 3005 (64.7)
Rectal or both 1636 (35.3)
*Comorbidity assessed using Charlson comorbidity index
#ACPS -Australian clinico-pathological staging
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Discussion
This study examined factors associated with disease-
specific survival in a population-wide cohort of CRC
patients with access to universal healthcare, with spe-
cific focus on identifying socioeconomic and regional
disparities. As expected CRC survival was strongly as-
sociated with tumour characteristics at diagnosis (i.e.
poorer outcomes for more advanced stage and higher
grade). However we also found evidence of area level
socioeconomic and regional differences in survival for
certain subgroups of patients, after accounting for
clinical factors including stage. Outcomes were signifi-
cantly better for those living in the highest compared
with lowest SES neighbourhoods, with a more pro-
nounced effect for metastatic disease. We also ob-
served better outcomes among privately insured
patients with metastatic disease. Significantly worse
outcomes were observed among those living in re-
mote compared with metropolitan regions, though
this applied to potentially curable disease only.
While our results suggest that CRC survival differs
according to SES, despite provision of universal health-
care services, some observations weaken this conclu-
sion. There was no clear ‘dose response’ with increasing
SES. Among stage A-C cases, risk differences for the
highest compared with lowest SES areas did not reach
statistical significance when restricted to those with
stage A-C disease. Furthermore, our measure of SES
was based on characteristics of an individual’s neigh-
bourhood, rather than individual measures such as the
person’s education, occupation or income level. Thus,
there is potential for misclassification of SES at the in-
dividual level, which may have led to inaccurate
findings.
The existing body of international literature show-
ing socioeconomic inequalities in CRC survival, across
numerous countries with differing health care systems
[7–12], supports our findings. Many of these studies
show that disparities persist after adjustment for dif-
ferences in stage [20]. Evidence from Australian-based
Table 2 Crude and adjusted odds ratios for factors associated with later stage at diagnosis derived from ordinal logistic regression
(unknown stage excluded) N = 4362
Crude Adjusted#
Variables OR 95 % CI p-value OR 95 % CI p-value
Site Colon 1.00 1.00
Rectum 0.82 0.73-0.91 <0.001 0.81 0.72-0.91 <0.001
Age group 50-59 yrs 1.00 1.00
60-69 yrs 0.82 0.70-0.95 <0.008 0.76 0.66-0.89 <0.001
70-79 yrs 0.88 0.77-1.02 0.087 0.77 0.67-0.89 0.001
Sex Females 1.00 1.00
Males 0.97 0.87-1.08 0.562 0.96 0.86-1.07 0.436
SES Lowest (quintile) 1.00 1.00
Low 0.89 0.75-1.06 0.208 0.90 0.75-1.08 0.248
Mid 0.99 0.83-1.18 0.909 0.96 0.79-1.15 0.636
Low-high 0.93 0.78-1.10 0.395 0.90 0.75-1.08 0.268
Highest 1.08 0.91-1.26 0.438 1.03 0.86-1.23 0.756
Residence Inner urban 1.00 1.00
Outer urban 0.85 0.70-1.05 0.080 0.89 0.74-1.07 0.248
Rural 1.02 0.88-1.20 0.717 0.99 0.83-1.16 0.812
Remote 0.92 0.73-1.16 0.473 0.99 0.77-1.26 0.912
Private Insurance No 1.00 1.00
Yes 0.88 0.76-0.94 0.002 0.84 0.75-0.95 0.003
Co-morbidities None 1.00 1.00
One (not severe) 1.25 1.09-1.44 0.002 1.25 1.09-1.44 0.002
Multiple or severe 1.48 1.25-1.76 <0.001 1.50 1.26-1.79 <0.001
Diagnosis year 2003-2008 (cont) 0.97 0.94-1.00 0.024 0.97 0.94-1.00 0.027
#Ordinal logistic regression model adjusted for all factors simultaneously – excludes missing stage (n = 328)
Ordinal logistic regression is an extension of logistic regression that incorporates the ordinal nature of the dependent variable (in this case stage at diagnosis). It
can be used for modelling a dependant variable that has more than two ordered categories. The method is analogous to a series of binary models predicting the
following combinations of binary stage groupings (e.g. stage A v stage B + C + D, A + B v C + D and A + B + C v D)
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studies is mixed. Hall et al. (Western Australia) [33]
and Jorgensen et al. (New South Wales) [34] found
no association between SES and CRC outcomes, while
Kelsall et al. (Victoria) [35], Morris et al. (Western
Australia) [36] and Baade et al. (Queensland) [18] did
observed socioeconomic disparities. All used area-
Table 3 1, 3 and 5 year colorectal cancer cancer-specific survival [%], for South Australian residents aged 50-79 yr, diagnosed
2003-2008 (unadjusted). [N = 8461]
CRC-survival (%) 1 yr 95 % CI 3 yrs 95 % CI 5 yrs 95 % CI p-value#
Total 88 87 - 89 75 73 - 76 69 68 - 71
Age group 50-59 yrs 91 89 - 92 75 72 - 78 68 65 - 71
60-69 yrs 90 88 - 91 76 74 - 79 70 67 - 72 0.016
70-79 yrs 85 84 - 87 71 69 - 72 66 64 - 68
Sex Female 88 86 - 89 74 72 - 76 69 66 - 71 0.156
Male 88 87 - 89 74 72 - 75 67 65 - 69
Private Insurance No 85 83 - 86 71 69 - 73 65 62 - 67 <0.001
Yes 91 89 - 92 76 75 - 79 70 68 - 72
Residence Inner urban 88 87 - 89 75 72 - 76 69 66 - 69
Outer urban 87 84 - 90 76 71 - 80 71 66 - 75 0.219
Rural 86 83 - 89 74 69 - 76 68 64 - 71
Remote 89 83 - 92 73 66 - 79 64 56 - 70
Very remote 84 67 - 92 75 57 - 86 59 38 - 76
SES (quintiles) Least advantaged 86 84 - 88 70 69 - 75 64 61 - 67
Mid-low 87 85 - 89 74 71 - 77 68 65 - 71
Mid 87 85 - 89 74 72 - 78 69 66 - 72 0.010
Mid-high 89 87 - 91 74 72 - 78 67 64 - 70
Most advantaged 91 89 - 93 78 75 - 81 71 68 - 74
ACP Stage A 98 97 - 99 97 95- 98 95 93 - 96
B 97 95 - 97 89 87 - 90 84 82 - 86
C 91 89 - 92 72 69 - 74 62 59 - 64 <0.001
D 54 50 - 58 18 15 - 21 9 7 - 12
Unknown 72 66 - 77 58 51 - 63 56 49 - 62
Grade Low 93 87 - 97 87 79 - 92 85 77 - 90
Intermediate 93 92 - 94 81 80 - 82 75 73 - 76 <0.001
High 77 74 - 79 55 52 - 58 49 46 - 53
Unknown 66 61 - 71 47 41 - 52 43 37 - 48
Site Colon 87 86 - 88 73 72 - 74 68 66 - 69
Rectum 90 88 - 91 76 73 - 78 68 66 - 70 0.747
Co-morbidity None 90 89 - 91 77 75 - 78 70 69 - 72
One (not severe) 87 85 - 89 73 70 - 76 68 64 - 71 <0.001
Multiple / severe 75 71 - 78 58 54 - 62 52 48 - 56
Surgery† No 46 41 - 51 24 20 - 28 19 16 - 24 <0.001
Yes 92 91 - 93 79 77 - 80 73 71 - 74
Radiotherapy† No 88 87 - 89 75 74 - 76 70 68 - 71 <0.001
Yes 87 84 - 89 67 63 - 71 57 53 - 61
Chemotherapy† No 88 87 - 89 81 79 - 82 77 75- 79 <0.001
Yes 88 86 - 89 62 59 - 64 52 50 - 55
#Kaplan-meier log rank test
†Treatments received within 12 months of diagnosis
Mean follow-up time to death or censoring of 40 months (sd = 24 months), median 36 months (inter-quartile range 21-59 months
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level measures of SES compiled by the ABS. Our
findings provide further evidence of inequalities in
CRC according to area-level deprivation in Australia,
despite universal access to health care, with similar
effect sizes to previous Australian studies (~25 %
difference for highest to lowest SES groups) but
slightly lower than international estimates [20].
Various explanations for socioeconomic disparities in
CRC survival include differences in screening patterns,
distribution of stage of disease, lifestyle factors, co-
Table 4 Multivariate competing risks regression analysis for risk of CRC death, all CRC patients
CRC death/
no. at risk
All CRC (n = 4365)
HR 95 % CI p-value
Site Colon 923/2847 1.00 - -
Rectum 487/1518 0.85 0.74-0.98 0.022
Stage dukes A 55/933 1.00 - -
B 250/1438 2.97 2.21-3.99 0.000
C 520/1345 7.74 5.75-10.4 0.000
D 585/649 34.1 25.0-46.5 0.000
Grade Low 10/114 1.00 - -
Intermediate 826/3137 1.22 0.72-2.07 0.453
High 405/825 2.25 1.32-3.84 0.003
Unknown 159/289 2.09 1.20-3.64 0.010
Age group 50-59 298/901 1.00 - -
60-69 467/1552 1.04 0.89-1.21 0.600
70-79 645/1942 1.12 0.96-1.29 0.146
Sex Female 585/1867 1.00 - -
Male 825/2498 1.07 0.95-1.20 0.243
Private Insurance No 686/1985 1.00 - -
Yes 724/2380 0.95 0.84-1.06 0.335
Comorbidity None 941/3068 1.00 - -
One (not severe) 248/779 0.90 0.78-1.05 0.194
Multiple / severe 221/518 1.21 1.02-1.44 0.033
SES quintile Low 382/1072 1.00 - -
Low-mid 280/878 0.94 0.80-1.11 0.443
Middle 246/791 0.93 0.78-1.10 0.379
Mid-high 276/843 1.06 0.90-1.25 0.508
High 226/781 0.75 0.62-0.91 0.004
Residence Urban 1007/3102 1.00 - -
Outer urban 122/429 0.95 0.79-1.16 0.638
Rural 47/188 0.98 0.82-1.17 0.830
Remote 93/242 1.12 0.90-1.39 0.324
Surgerya No 230/295 1.00 - -
Yes 1180/4070 0.51 0.42-0.62 0.000
Radiotherapya No 1141/3757 1.00 - -
Yes 36/269 1.41 1.18-1.68 0.000
Chemotherapya No 632/2745 1.00 - -
Yes 778/1620 0.87 0.76-1.00 0.047
Diagnosis year (continuous) 1410/4365 0.95 0.92-0.98 0.002
CRC patients age 50-79 years diagnosed in South Australia 2003–3008
Analysis with multiply imputed stage and grade, where missing, revealed similar results (i.e. identical patterns with regard to significant associations and
approximately equivalent point estimates for all HRs)
aTreatments received within 12 months of diagnosis
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morbidities, access to health care services and inequal-
ities in treatments. In their review, Aarts et al. note the
difficulty in attributing SES differences in survival to any
one specific factor [20]. Likewise, Palmer and Schneider
highlight socioeconomic disparities across the spectrum
of colorectal cancer control including early detection,
diagnosis, treatment and outcomes, and call for a multi-
disciplinary approach to tackling inequalities [21]. Since
we found no evidence of differences in stage distribution
according to SES, it is unlikely that disparities are due to
more advanced disease stage in areas with low SES. Fur-
thermore we adjusted for stage in our regression models.
Table 5 Multivariate competing risks regression analysis for risk of death from CRC, for stages A-C
Covariates No. CRC
deaths/total
Stages A-C (n = 3716)
HR 95 % CI p-value
Site Colon 523/2409 1.00 - -
Rectum 302/1307 0.94 0.78-1.14 0.538
Stage dukes A 55/933 1.00 - -
B 250/1438 2.93 2.18-3.94 0.000
C 520/1345 6.72 4.92-9.17 0.000
Grade Low 12/104 1.00 - -
Intermediate 512/2779 1.09 0.61-1.95 0.779
High 262/670 2.13 1.18-3.87 0.013
Unknown 39/163 1.59 0.82-3.07 0.172
Age group 50-59 172/758 1.00 - -
60-69 282/1317 1.08 0.89-1.31 0.433
70-79 371/1641 1.12 0.93-1.36 0.240
Sex Female 348/1604 1.00 - -
Male 477/2112 1.09 0.94-1.26 0.243
Private Insurance No 352/1625 1.00 - -
Yes 473/2091 1.07 0.92-1.24 0.378
Comorbidity None 580/2672 1.00 - -
One (not severe) 142/653 0.94 0.77-1.13 0.504
Multiple / severe 103/391 1.29 1.02-1.62 0.032
SES quintile Low 216/890 1.00 - -
Low-mid 164/749 0.98 0.79-1.20 0.819
Middle 142/678 0.80 0.63-1.00 0.048
Mid-high 169/730 1.00 0.80-1.24 0.967
High 134/669 0.80 0.63-1.01 0.057
Residence Urban 578/2624 1.00 - -
Outer urban 74/374 0.96 0.74-1.23 0.724
Rural 117/515 0.94 0.75-1.17 0.561
Remote 56/203 1.35 1.01-1.80 0.040
Surgerya No 41/96 1.00 - -
Yes 784/3620 0.38 0.26-0.56 0.000
Radiotherapya No 656/3217 1.00 - -
Yes 169/499 1.48 1.16-1.88 0.002
Chemotherapya No 399/2487 1.00 - -
Yes 426/1229 1.11 0.92-1.35 0.284
Diagnosis year (continuous) 825/3716 0.93 0.90-0.97 0.002
CRC patients age 50-79 years diagnosed in South Australia 2003–2008
Analysis with multiply imputed stage and grade, where missing, revealed similar results (i.e. identical patterns with regard to significant associations and
approximately equivalent point estimates for all HRs)
aTreatments received within 12 months of diagnosis
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While we also adjusted for co-morbidities using the
Charlson co-morbidity index, we were unable to adjust
for general lifestyle factors such as obesity, tobacco use,
lack of physical activity, due to the lack of individual
level data, so cannot rule out the influence of these fac-
tors. Our previous research found no overall difference
in compliance with treatment guidelines, though
radiotherapy for rectal cancer was less likely among
more advantaged groups [37]. No differences were ob-
served for surgery or chemotherapy by SES. Differences
in treatment (at the broad level) do not explain survival
patterns in the current study. Furthermore, inclusion of
treatments in regression models did not attenuate the ob-
served associations with survival outcomes. However,
Table 6 Multivariate competing risks regression analysis for risk of death from CRC, for stage D CRC
Covariates No. CRC
deaths/total
Stage D (n = 649)
HR 95 % CI p-value
Site Colon 400/438 1.00 - -
Rectum 185/211 0.71 0.58-0.87 0.001
Stage dukes A - - -
B - - -
C - - -
Grade Low 8/10 1.00 - -
Intermediate 314/358 1.25 0.53-2.94 0.605
High 143/155 2.04 0.86-4.83 0.105
Unknown 120/126 2.26 0.94-5.42 0.067
Age group 50-59 126/143 1.00 - -
60-69 185/205 1.15 0.90-1.47 0.254
70-79 274/301 1.15 0.90-1.46 0.261
Sex Female 237/263 1.00 - -
Male 348/386 1.11 0.92-1.33 0.295
Private Insurance No 334/360 1.00 - -
Yes 251/289 0.80 0.67-0.96 0.016
Comorbidity None 361/396 1.00 - -
One (not severe) 106/126 0.87 0.68-1.11 0.259
Multiple / severe 118/127 1.13 0.87-1.45 0.364
SES quintile Low 166/182 1.00 - -
Low-mid 116/129 0.85 0.65-1.11 0.231
Middle 104/113 1.07 0.81-1.41 0.622
Mid-high 107/113 1.15 0.90-1.48 0.259
High 92/112 0.65 0.47-0.89 0.007
Residence Urban 429/478 1.00 - -
Outer urban 48/55 1.00 0.74-1.34 0.975
Rural 71/77 1.05 0.79-1.41 0.724
Remote 37/39 0.91 0.67-1.23 0.553
Surgerya No 189/199 1.00 - -
Yes 396/450 0.58 0.46-0.72 0.000
Radiotherapya No 485/540 1.00 - -
Yes 100/109 1.25 0.98-1.58 0.068
Chemotherapya No 233/258 1.00 - -
Yes 352/391 0.62 0.51-1.04 0.000
Diagnosis year (continuous) 585/649 0.99 0.94-1.04 0.619
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other treatment related factors like continuation of
chemotherapy, resection of liver metastases and access to
follow-up care may vary by SES. Further investigation is
warranted to determine the mediating pathways for these
disparities.
Our study also found poorer outcomes for those from
remote locations for stage A to C disease. Regional dis-
parities were not observed for metastatic (stage D) dis-
ease, which is consistent with previous finding from
clinical registry data [38]. Some caution in our inter-
pretation is warranted given we did not observed any
significant differences in the whole study population.
Distance from treatment facilities has previously been
shown to impact CRC survival in Australia [17, 18],
and internationally [13–16]. Baade et al. [17], found
that risk of mortality from rectal cancer increased by
6 % with every 100 km distance from a radiotherapy
centre for rectal patients in Queensland (Australia). In
a subsequent study the same authors also found that
CRC patients residing in remote locations had 14 %
lower 5 yr-survival compared with their urban counter-
parts [18]. Similar to our finding, they noted disparities
only in relation to residents from remote locations.
They hypothesise that regional differences may be due
Fig. 2 Cumulative CRC mortality by a SES quintiles (for all cases 3 middle quintiles collapsed) and b remoteness of residence (cases with stages
A-C at diagnosis) Fig. 2a and b represent cumulative incidence plots for CRC mortality by based on competing risk regression, for CRC
cases diagnosed 2003-2008 among South Australians aged 50-79 yrs. Covariates include age, tumour site, stage, grade, co-morbidity,
health insurance status, treatments received in first 12 months, and diagnosis year, categorised as described in methods. SES quintiles
low-mid, mid, mid-high were collapsed into one category
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to patient factors (lifestyle factors and co-morbidities)
as well as management patterns, and clinical experience
in regional hospitals. We were unable to identify any
obvious pathway through which regional disparities in
survival could be explained. Poorer survival among pa-
tients from remote areas with stage A-C CRC suggest
inequalities in access to, or quality of, care rather than
regional differences in stage at diagnosis. Findings from
our previous patterns of care study (in the same cohort)
indicated that rural and remote patients with stage C
colon cancer were less likely to receive chemotherapy
[37], which may be one reason for poorer outcomes.
Differences in follow-up care after initial treatment by
place of residence may be another explanation. Again
further research to address the causes of poorer sur-
vival among potentially curable patients from more re-
mote areas is required.
We also observed differences in survival according to
treatment modalities. Patients who underwent surgery
or received chemotherapy (for Stage D disease) had bet-
ter survival while patients who recieved radiotherapy
had poorer outcomes than those not receiving these
treatments. Reasons for better outcomes with surgery
are likely to relate to patients’ fitness for surgery or inop-
erability of the tumour. Likewise receipt of chemother-
apy is less likely among frail or unfit patients, who are
also likely to have poorer survival outcomes. Thus the
results would be consistent with decisions not to offer
chemotherapy when there is likely to be limited effect-
iveness, high risk of side effects, or both. Poorer cancer
specific survival among radiotherapy recipients may be
due to radiotherapy being given with palliative rather
than curative intent in some cases.
Strengths and limitations
This study demonstrates the utility of record linkage,
using administrative and health surveillance databases,
to evaluate disparities in outcomes for cancer patients.
Record linkage offers considerable advantages over
institutionally-based studies when examining disparities
according to socioeconomic status or place of residence
[39]. The inclusion of all eligible patients, regardless of
whether they attended public or private health care ser-
vices or both, greatly reduces the potential for selection
bias to have influenced our results.
Our findings in relation to SES are based on area-level
rather than individual level measures of SES, so may not
accurately measure the level of socioeconomic disadvan-
tage for individuals. Ideally, individual measures such as
income, education level, housing and car ownership
would be preferable, however these data are hard to ob-
tain at a population level. Area level measures of neigh-
bourhood deprivation are commonly used to identify
socioeconomic disparities at the population-wide level.
IRSAD is a rigorously constructed, composite measure
of socioeconomic advantage and disadvantage based on
census data for small areas which has been widely used
to assess SES disparities in Australia [40]. Previous data
linkage studies have been hampered by lack of staging
data or incomplete information on treatments, particu-
larly those provided through the private health sector.
While we made use of staging data from a previous re-
search project, cancer registries across Australia do not
routinely collect stage. High priority needs to be given
to developing sustainable systems to collect and record
staging information within central cancer registries to
enhance their value and usefulness in health outcomes
research. Cancer Australia initiatives to pilot the collec-
tion of staging information in Australian cancer regis-
tries are promising developments [41].
Concerns are often raised about the quality and
consistency of administrative data, particularly in rela-
tion to treatments and comorbidity [42]. Linkage across
multiple data sources including hospital admission re-
cords, clinical registries and public and private radio-
therapy services enhanced our ability to capture broad
level treatment information. Our study would have
been further enhanced had we had access to national
pharmaceutical prescription data, through linkage with
the national database, to better ascertainment of
chemotherapy administered in outpatient and commu-
nity settings [43]. The establishment of data integrating
authorities, which is underway throughout Australia,
will provide greater access to such data which are cru-
cial for evaluating effectiveness of cancer care [44].
While we acknowledge the limitations of using admin-
istrative data sources to determine treatment informa-
tion, undertaking case note reviews at a population
level would be impractical and the cost prohibitive.
Linkage derived measures are likely to be sufficient for
epidemiological studies, though further research is war-
ranted to valid measures and determine the impact of
inaccuracies on population-based research.
Conclusion
This study points to disparities in CRC survival in
South Australia according to socioeconomic charac-
teristics and remoteness of patients’ place of resi-
dence, despite universal access to healthcare. The
reasons for these disparities remain unclear, but do
not appear to be due to differences in stage or other
prognostic factors, age, comorbid disease burden or
treatment difference at a broad level, though access
to chemotherapy may be a contributing factor. Our
analyses were unable to account for individual life-
style risks, treatment differences at a more detailed
level, hospital/clinician volume or access to follow-up
care, some or all of which may be contributing to
Beckmann et al. BMC Health Services Research  (2016) 16:24 Page 12 of 14
these disparities. Further research is required to iden-
tify the underlying causes of these disparities which
can be addressed to achieve equitable outcomes for
all patients irrespective of social position or place of
residence.
Abbreviations
ACPS: Australian clinico-pathologic staging; CCI: Charlson Comorbidity Index;
CI: confidence interval; CRC: colorectal cancer; HBCR: hospital-based cancer
registry; HR: hazard ratio; IRSAD: Index of Relative Socioeconomic Advantage
and Disadvantage; NBCSP: National Breast Cancer Screening Program;
OR: odds ratio; SA: South Australia; SACR: South Australian Cancer Registry;
SES: socioeconomic status.
Competing interests
The authors declare they have no completing interests.
Authors’ contributions
DR and GY conceived the overall project and were responsible for the broad
conceptual design of this study. AB, GY, CK, DW, KB and DR each contributed
to the detailed design of this study. KB was responsible for data analysis and
drafting of the preliminary manuscript. AB, GY, SC, RJ, JA, NS, CK, DW and DR
provided input into the interpretation of findings and critically reviewed the
manuscript. All authors read and approved the final manuscript.
Acknowledgements
The authors wish to acknowledge the generous in-kind support and practical
assistance provided by SANT DataLink, Population Health Research Network,
the Epidemiology Branch of SA Health and the Cancer Council SA in under-
taking this research. Special thanks go to Ms Brit Catcheside for undertaking
linkage work within the Epidemiology Branch and to Ms Lesley Milliken and
Ms Susie Byrne for undertaking the staging of eligible cases.
This research was undertaken on behalf of the Colorectal Cancer Project
Team. The team consisted of the following individuals, in addition to the
authors listed on this paper: Dr. Anna Muller (Adelaide Radiotherapy Group);
Assoc. Prof. Eric Yeoh (Radiation Oncology, Royal Adelaide Hospital); Mrs.
Adeline Lim (Radiation Oncology, Royal Adelaide Hospital); Dr. Scott
Carruthers (Radiation Oncology, Royal Adelaide Hospital), Prof. Bik To (IMVS
Pathology); Dr. Paul Hollington (Colorectal Surgery, Flinders Medical Centre);
Dr. James Moore (Colorectal Surgery, Royal Adelaide Hospital), Mr. Tony
Woollacott (Department of Health, South Australian Government) and Mr.
Simeon Jones (Cancer Australia).
Author details
1Centre for Population Health Research, University of South Australia, GPO
Box 2471, Adelaide, SA 5001, Australia. 2Flinders Medical Centre, Flinders
Drive, Bedford Park, SA 5042, Australia. 3Flinders Centre for Innovation in
Cancer, Flinders University, Flinders Drive, Bedford Park, SA 5042, Australia.
4Country Health SA, Adelaide, SA 5000, Australia. 5Lyell McEwin Hospital,
Elizabeth Vale, SA 5112, Australia. 6Medical Oncologist, Royal Adelaide
Hospital, University of Adelaide, Adelaide, SA 5001, Australia. 7South Adelaide
Health Network, Medical Oncology, Flinders Medical Centre, Flinders Drive,
Bedford Park, SA 5042, Australia. 8Flinders University, Flinders Medical Centre,
Bedford Park, SA 5042, Australia.
Received: 15 April 2015 Accepted: 8 January 2016
References
1. Globocan 2012 v1.0: Cancer incidence, mortality and prevalence worldwide:
IARC CancerBase No. 11 [http://globocan.iarc.fr]. Accessed April 2015.
2. Australian Institute of Health and Welfare, Australasian Association of Cancer
Registries: Cancer in Australia: an overview, 2012. Cancer series no. 74. Cat
no. CAN 70. Canberra: AIHW; 2012.
3. Australian Institute of Health and Welfare: Health system expenditure on
cancer and other neoplasms in Australia 2008-09. Cancer series no. 81. Cat.
no. CAN 78. Canberra: AIHW; 2013.
4. Cancer Institute NSW. Cancer survival in New South Wales 2002-2006.
Sydney: Cancer Institute NSW; 2012.
5. Cole SR, Tucker GR, Osborne JM, Byrne SE, Bampton PA, Fraser RJ, et al. Shift
to earlier stage at diagnosis as a consequence of the National Bowel Cancer
Screening Program. Med J Aust. 2013;198(6):327–30.
6. Australian Institute of Health and Welfare. Analysis of bowel cancer
outcomes for the National Bowel Cancer Screening Program . Cat. no. CAN
87. Canberra: AIHW; 2014.
7. Byers TE, Wolf HJ, Bauer KR, Bolick-Aldrich S, Chen VW, Finch JL, et al. The
impact of socioeconomic status on survival after cancer in the United States :
findings from the National Program of Cancer Registries Patterns of Care
Study. Cancer. 2008;113(3):582–91.
8. Eloranta S, Lambert PC, Cavalli-Bjorkman N, Andersson TM, Glimelius B,
Dickman PW. Does socioeconomic status influence the prospect of cure
from colon cancer -a population-based study in Sweden 1965–2000. Eur J
Cancer. 2010;46(16):2965–72.
9. Frederiksen BL, Osler M, Harling H, Ladelund S, Jorgensen T. Do patient
characteristics, disease, or treatment explain social inequality in survival
from colorectal cancer? Soc Sci Med. 2009;69(7):1107–15.
10. Hole DJ, McArdle CS. Impact of socioeconomic deprivation on outcome
after surgery for colorectal cancer. Br J Surg. 2002;89(5):586–90.
11. Shaw C, Blakely T, Sarfati D, Fawcett J, Peace J. Trends in colorectal
cancer mortality by ethnicity and socio-economic position in New
Zealand, 1981-99: one country, many stories. Aust N Z J Public Health.
2006;30(1):64–70.
12. Whynes DK, Frew EJ, Manghan CM, Scholefield JH, Hardcastle JD. Colorectal
cancer, screening and survival: the influence of socio-economic deprivation.
Public Health. 2003;117(6):389–95.
13. Dejardin O, Bouvier AM, Faivre J, Boutreux S, De Pouvourville G, Launoy G.
Access to care, socioeconomic deprivation and colon cancer survival.
Aliment Pharmacol Ther. 2008;27(10):940–9.
14. Hines RB, Markossian TW. Differences in late-stage diagnosis, treatment, and
colorectal cancer-related death between rural and urban African Americans
and whites in Georgia. J Rural Health. 2012;28(3):296–305.
15. Lian M, Schootman M, Doubeni CA, Park Y, Major JM, Stone RA, et al.
Geographic variation in colorectal cancer survival and the role of small-area
socioeconomic deprivation: a multilevel survival analysis of the NIH-AARP
Diet and Health Study Cohort. Am J Epidemiol. 2011;174(7):828–38.
16. Singh GK, Williams SD, Siahpush M, Mulhollen A. Socioeconomic, Rural-
Urban, and Racial Inequalities in US Cancer Mortality: Part I-All Cancers and
Lung Cancer and Part II-Colorectal, Prostate, Breast, and Cervical Cancers.
Journal of Cancer Epidemiology. 2011;2011:107497.
17. Baade PD, Dasgupta P, Aitken JF, Turrell G. Distance to the closest
radiotherapy facility and survival after a diagnosis of rectal cancer in
Queensland. Med J Aust. 2011;195(6):350–4.
18. Baade PD, Dasgupta P, Aitken JF, Turrell G. Geographic remoteness, area-
level socioeconomic disadvantage and inequalities in colorectal cancer
survival in Queensland: a multilevel analysis. BMC Cancer. 2013;13:493.
19. Australian Institute of Health and Welfare. Cancer survival and prevalence in
Australia: period estimates from 1982-2010. Cancer series no. 69. CAN 65.
Canberra: AIHW; 2012.
20. Aarts MJ, Lemmens VE, Louwman MW, Kunst AE, Coebergh JW. Socioeconomic
status and changing inequalities in colorectal cancer? A review of the
associations with risk, treatment and outcome. Eur J Cancer. 2010;46(15):2681–95.
21. Palmer RC, Schneider EC. Social disparities across the continuum of colorectal
cancer: a systematic review. Cancer Causes & Control. 2005;16(1):55–61.
22. Baade PD, Turrell G, Aitken JF. A multilevel study of the determinants of
area-level inequalities in colorectal cancer survival. BMC Cancer. 2010;10:24.
23. Gorey KM, Luginaah IN, Bartfay E, Fung KY, Holowaty EJ, Wright FC, et al.
Effects of socioeconomic status on colon cancer treatment accessibility and
survival in Toronto, Ontario, and San Francisco, California, 1996-2006. Am J
Public Health. 2011;101(1):112–9.
24. Young JM, Leong DC, Armstrong K, O’Connell D, Armstrong BK, Spigelman
AD, et al. Concordance with national guidelines for colorectal cancer care in
New South Wales: a population-based patterns of care study. Med J Aust.
2007;186(6):292–5.
25. Kelman CW, Bass AJ, Holman CD. Research use of linked health data -a best
practice protocol. Aust N Z J Public Health. 2002;26(3):251–5.
26. Davis NC, Newland RC. The reporting of colorectal cancer: the Australian
Clinico-pathological Staging (ACPS) System. Med J Aust. 1983;1(6):282.
27. Department of Health and Aged Care. Measuring Remoteness: Accessibility/
Remoteness Index for Australia (ARIA), Revised Edition. In: Occasional paper:
New series no14. Canberra: Dept Health and Aged Care; 2001.
Beckmann et al. BMC Health Services Research  (2016) 16:24 Page 13 of 14
28. Australian Bureau of Statistics. Information Paper: An Introduction to
Socio-Economic Indexes for Areas (SEIFA) 2006. Canberra: ABS; 2008.
29. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying
prognostic comorbidity in longitudinal studies: development and validation.
J Chronic Dis. 1987;40(5):373–83.
30. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a
competing risk. Journal of American Statistical Association. 1999;94(446):
496–509.
31. White IR, Royston P, Wood AM. Multiple imputation using chained
equations: Issues and guidance for practice. Stat Med. 2011;30(4):377–99.
32. StataCorp. Stata Statisitical Software: Release 12. College Station: StatCorp
LP; 2010.
33. Hall SE, Holman CD, Platell C, Sheiner H, Threlfall T, Semmens J. Colorectal
cancer surgical care and survival: do private health insurance,
socioeconomic and locational status make a difference? ANZ J Surg. 2005;
75(11):929–35.
34. Jorgensen ML, Young JM, Dobbins TA, Solomon MJ. Predictors of variation
in colorectal cancer care and outcomes in New South Wales: a population-
based health data linkage study. Med J Aust. 2014;200(7):403–7.
35. Kelsall HL, Baglietto L, Muller D, Haydon AM, English DR, Giles GG. The effect
of socioeconomic status on survival from colorectal cancer in the
Melbourne Collaborative Cohort Study. Soc Sci Med. 2009;68(2):290–7.
36. Morris M, Iacopetta B, Platell C. Comparing survival outcomes for patients
with colorectal cancer treated in public and private hospitals. Med J Aust.
2007;186(6):296–300.
37. Beckmann KR, Bennett A, Young GP, Roder DM. Treatment patterns among
colorectal cancer patients in South Australia: a demonstration of the utility
of population-based data linkage. J Eval Clin Pract. 2014;20(4):467–77.
38. Singla A, Broadbridge V, Mittinty M, Beeke C, Maddern GJ. Rural populations
have equal surgical and survival outcomes in metastatic colorectal cancer.
Aust J Rural Health. 2014;22(5):249–56.
39. Hall SE, Holman CD, Finn J, Semmens JB. Improving the evidence base for
promoting quality and equity of surgical care using population-based
linkage of administrative health records. International J Qual Health Care.
2005;17(5):415–20.
40. Glover J, Rosman DL, Tennant S. Unpacking analyses relying on area-based
data: are assumptions supportable? Int J Health Geogr. 2004;3(1):30–42.
41. Cancer Australia. Cancer data to improve cancer survival. [http://canceraustralia.
gov.au/research-data/cancer-data/cancerdata-improve-cancer-survival].
Accessed April 2015.
42. Goldsbury DE, Armstrong K, Simonella L, Armstrong BK, O’Connell DL. Using
administrative health data to describe colorectal and lung cancer care in
New South Wales, Australia: a validation study. BMC Health Serv Res. 2012;
12:387.
43. Goldsbury DE, Smith DP, Armstrong BK, O’Connell DL. Using linked routinely
collected health data to describe prostate cancer treatment in New South
Wales, Australia: a validation study. BMC Health Serv Res. 2011;11:253.
44. Australian Government National Statistical Services. Data integration
involving Commonwealth data for statistical and research purposes:
Governance and institutional arrangements. [http://www.nss.gov.au/nss/
home.nsf/NSS/0E887A88A9224F8BCA2577F20016FE5D?opendocument].
Accessed April 2015.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Beckmann et al. BMC Health Services Research  (2016) 16:24 Page 14 of 14
